Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SCC vs RXD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RXD Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)

RXD Overall Winner 6-Pillar Tally: SCC 0 – 0 RXD (6 Tie) Matrix Metrics: SCC 0 – 3 RXD

As of Nov 16, 2026, ProShares UltraShort Health Care (RXD) is the stronger overall head-to-head candidate over ProShares UltraShort Consumer Discretionary (SCC) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). SCC carries a Unified Composite Score of 56.5/100 (HOLD) at $14.00 (N/M Forward P/E, N/A operating margin), whereas RXD carries 58.1/100 (HOLD) at $11.95 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: SCC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.9); meanwhile RXD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SCC vs RXD
SCC NYSE Arca
ProShares UltraShort Consumer Discretionary
Institutional Equity
$14.00
+3.03% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -2.18β · 54% Vol
Unified Composite Score
56.5 / 100 HOLD
Tech 71.0 Fund 63.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.9 · SMA20: $14.25 · SMA50: $15.24
RXD NYSE Arca Head-to-Head Winner
ProShares UltraShort Health Care
Institutional Equity
$11.95
+1.01% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.21β · 40% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 80.0 Fund 66.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.9%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $12.44 · SMA50: $13.87

6-Pillar Scorecard Institutional Category Breakdown (SCC 0 – 0 RXD)

Columns: Metric · SCC · RXD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 95.8% (100th %ile) 25.2% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SCC (0) vs RXD (3)
Institutional Metric SCC RXD Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
20% ($13–$18) 29% ($8–$21) Stronger Trend RXD
Beta / 30D Volatility
Risk Regime
-2.18β · 54% Vol -0.21β · 40% Vol Lower Realized Risk RXD
Unified Institutional Score
Composite Signal
56.5 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite RXD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SCC +1.62 pp
SCC: -10.22% · RXD: -11.84%
3M Horizon SCC +15.41 pp
SCC: -4.31% · RXD: -19.72%
6M Horizon RXD +22.53 pp
SCC: -6.47% · RXD: +16.06%
1Y Horizon RXD +35.87 pp
SCC: -8.97% · RXD: +26.9%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SCC vs RXD. Trailing 12-month operating profitability (SCC N/A vs RXD N/A) and valuation multiples (SCC N/M vs RXD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SCC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
RXD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RXD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 25.2%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RXD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SCC Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RXD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SCC vs RXD Key Questions & Quantitative Answers

As of Nov 16, 2026, ProShares UltraShort Health Care (RXD) is the stronger overall head-to-head candidate over ProShares UltraShort Consumer Discretionary (SCC) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). SCC carries a Unified Composite Score of 56.5/100 (HOLD) at $14.00 (N/M Forward P/E, N/A operating margin), whereas RXD carries 58.1/100 (HOLD) at $11.95 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: SCC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.9); meanwhile RXD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SCC and RXD split Growth & Scale metrics: SCC posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RXD at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, SCC generates N/A in USD-normalized revenue versus N/A for RXD. In operating R&D and SG&A reinvestment, SCC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RXD.

SCC and RXD trade at balanced relative valuation multiples. SCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RXD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SCC (N/A ROE) versus RXD (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, SCC carries 95.8% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-2.18β · 54% Vol realized risk). By comparison, RXD carries 25.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.21β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.